Latest Breaking News On - Euronext growth stock exchange - Page 2 : vimarsana.com

PHARNEXT: Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A

PHARNEXT: Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A

Pharnext Sa : Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A -November 23, 2023 at 02:35 am EST

PARIS, France, November 23, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.

Pharnext Sa : Pharnext receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR500m and the support of its financial partners -October 30, 2023 at 03:40 am EDT

PARIS, France, October 30, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.

Pharnext Sa : Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) -September 28, 2023 at 02:35 am EDT

PARIS, France, 28 September 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.

PHARNEXT: Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)

PHARNEXT: Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot Marie Tooth disease type 1A, enabling it to capitalize on its assets and put an end to the OCEANE BSA financing line

Pharnext Sca : Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot Marie Tooth disease type 1A, enabling it to capitalize on its assets and put an end to the OCEANE BSA financing line -September 20, 2023 at 02:35 am EDT

Pharnext SCA , a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, today announces that it is in the final.

PHARNEXT: Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

PHARNEXT: Balance sheet liabilities reduced by almost EUR8 million following a debt waiver